Gossamer Bio
GOSS | NASDAQ
$10.98
+$0.01 (+0.09%)
At close: Nov 16, 2026, 4:00 PM ET
$10.98
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:39 PM ET
Gossamer Bio Company Profile
Company profile explainedCompany Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman |
| Bryan Giraudo | Chief Operating Officer & Chief Financial Officer |
| Caryn L. Peterson | Chief Development Officer |
| Christian Waage | Executive Vice President, Technical Operations & General Counsel |
| Conor O'Donovan | Senior Vice President of Regulatory Affairs |
| Deanna Weber | Executive Vice President of Human Resources |
| Jean-Marie Bruey | Senior Vice President of Translational Medicine & Research |
| Jeanine Anthony | Senior Vice President of Marketing |
| Kelly Dawson | Senior Vice President & Program Team Lead |
| Robert F. Roscigno | Senior Vice President of Clinical Development of Pulmonary Vascular Disease |
| Robert Smith | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | SC 13D/A | [Amend] Filing |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 08, 2026 | SC 13D/A | [Amend] Filing |
| Sep 28, 2026 | SC 13D/A | [Amend] Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
Gossamer Bio
| Country | United States |
| IPO Date | Feb 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 162 |
| CEO | Faheem Hasnain |
Contact Details
3115 Merryfield Row San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | GOSS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001728117 |
| CUSIP Number | 38341P201 |
| ISIN Number | US38341P2011 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove GOSS